Silexion Therapeutics Corp., a clinical-stage biotechnology company, has announced promising results from a preclinical study showcasing the significant efficacy of their RNA interference therapy, SIL204, in human lung cancer cell lines. The study demonstrated dose-dependent inhibition in cells with KRAS G12D mutations, supporting SIL204's potential as a versatile therapeutic for lung cancer. The company is also conducting additional studies on a previously untested KRAS mutation, with results expected to be released in the near future. Silexion plans to initiate a Phase 2/3 clinical trial in the second quarter of 2026 to further investigate SIL204 for the treatment of KRAS-driven solid tumor cancers.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。